clinicaltrials.pharmaceutical-business-review.com Report : Visit Site

Technical data of the clinicaltrials.pharmaceutical-business-review.com

Geo IP provides you such as latitude, longitude and ISP (Internet Service Provider) etc. informations. Our GeoIP service found where is host clinicaltrials.pharmaceutical-business-review.com. Currently, hosted in United Kingdom and its service provider is Progressive Digital Media .

the related websites

jenner.ac.uk ndorms.ox.ac.uk genetherapynet.com implementationscience.com nottingham.ac.uk eyeforpharma.com neurotransmitter.net daymarkrecovery.org evaluategroup.com thebraintumourcharity.org trialsbits.co.uk outsourcing-pharma.com economictimes.indiatimes.com bumpy.org.uk icmje.org xfurth.com jameslindlibrary.org products.office.com sparknotes.com 

HTTP Header Analysis

HTTP Header information is a part of HTTP protocol that a user's browser sends to called Microsoft-IIS/8.0, 15_16 containing the details of what the browser wants and will accept back from the web server.

DNS

HtmlToText

clinical trials industry news - contract research & services - pharmaceutical business review -- jump to page content accessibility log in or register for enhanced features | forgotten password? or register for enhanced features-- white papers | suppliers | events | report store | companies | dining club | medical devices | videos production & manufacturing fine & speciality chemicals manufacturing process & production otc digital transformation intelligent edge enable digital optimise core -- drug research drug delivery drug discovery & development digital transformation intelligent edge enable digital optimise core -- contract research & services clinical trials contract research contract services digital transformation intelligent edge enable digital optimise core -- automation it & software laboratory instrumentation digital transformation intelligent edge enable digital optimise core -- inward investment packaging regulatory affairs digital transformation intelligent edge enable digital optimise core -- medical devices -- contract research & services clinical trials all pbr | clinical trials clinical trials home | news | white papers | suppliers | companies return to: pbr home | contract research & services | clinical trials select a pharmaceutical sector ------------------------ fine & speciality chemicals manufacturing process & production otc ------------------------ drug delivery drug discovery & development ------------------------ clinical trials contract research contract services ------------------------ it & software laboratory instrumentation ------------------------ inward investment packaging regulatory affairs contract research & services clinical trials grünenthal begins phase iii trials in complex regional pain syndrome grünenthal has recruited first patients in two trials of pivotal phase iii program to investigate neridronate for the treatment of complex regional pain syndrome (crps). contract research & services > clinical trials > news astrazeneca, eli lilly terminate clinical trials of alzheimer's disease treatment lanabecestat by pbr staff writer astrazeneca and eli lilly have announced the termination of global phase 3 clinical trials of alzheimer's disease treatment, lanabecestat, which is an oral beta secretase cleaving enzyme (bace) inhibitor. contract research & services > clinical trials > news advaxis doses first patient with adxs-neo cancer immunotherapy advaxis has started a phase 1 trial with the dosing of the first patient with adxs-neo, an investigational personalized immunotherapy candidate targeting personal neoantigens found by sequencing a patient’s own cancer cells. contract research & services > clinical trials > news see more clinical trials news latest clinical trials news and insight view all clinical trials news or find news targeted to your interests fda accepts cellenkos’ ind to begin clinical trial of ck0801 for bone marrow failure syndromes the us food and drug administration (fda) has cleared cellenkos’ investigational new drug (ind) application to proceed with a phase i clinical trial of ck0801, third party cord blood derived regulatory t cells, in patients with bone marrow failure syndrome including aplastic anemia, myelodysplastic syndrome and myelofibrosis. contract research & services > clinical trials > news alnylam's lumasiran yields positive results in phase 1/2 hyperoxaluria study alnylam pharmaceuticals said that lumasiran, its investigational rnai therapeutic targeting glycolate oxidase (go) has yielded positive results from a phase 1/2 study in patients with primary hyperoxaluria type 1 (ph1). contract research & services > clinical trials > news abbvie’s upadacitinib succeeds in phase 3 trial in rheumatoid arthritis abbvie said that the phase 3 select-early trial evaluating two doses of upadacitinib (15 mg and 30 mg) as monotherapy in the treatment of rheumatoid arthritis met the primary endpoints of acr50a at week 12 and clinical remissionb at week 24 versus methotrexate (mtx). contract research & services > clinical trials > news astrazeneca says lynparza/abiraterone combo delayed disease progression in mcrpc by pbr staff writer astrazeneca has reported that lynparza (olaparib) in combination with abiraterone succeeded in a phase ii trial by delaying disease progression in metastatic castration-resistant prostate cancer (mcrpc) patients. contract research & services > clinical trials > news novartis phase iii trial shows kisqali combo therapy improves pfs in hr+/her2- advanced breast cancer novartis has reported positive results from the third phase iii trial of kisqali (ribociclib) in advanced or metastatic breast cancer. contract research & services > clinical trials > news merck’s keytruda shows improved orr in phase 2 renal cell carcinoma study by pbr staff writer a phase 2 trial assessing merck’s keytruda (pembrolizumab) demonstrated overall response rate (orr) of about 40% as first-line therapy in patients with advanced clear cell renal cell carcinoma (rcc). contract research & services > clinical trials > news syndax, nektar therapeutics announce immuno-oncology clinical trial collaboration syndax pharmaceuticals and nektar therapeutics have entered into a non-exclusive immuno-oncology clinical trial collaboration. contract research & services > clinical trials > news trial to test cancer combo in adults and children with leukaemia the combinations alliance, a joint initiative between cancer research uk and the experimental cancer medicine centres (ecmc) network based at university of birmingham, has launched a clinical trial testing a new treatment combination in patients with leukaemia. contract research & services > clinical trials > news madrigal’s liver drug succeeds in phase 2 clinical trial by pbr staff writer madrigal pharmaceuticals has said that its mgl-3196 thyroid hormone receptor (thr) β-selective agonist achieved liver biopsy endpoints in patients with non-alcoholic steatohepatitis (nash) at 36 weeks in phase 2 clinical trial. contract research & services > clinical trials > news janssen begins phase 1b/2 clinical trial to assess multiple myeloma treatment janssen has commenced a phase 1b/2 clinical development program to assess jnj-68284528 (developed based on legend’s lcar-b38m), a chimeric antigen receptor t cell (car-t) therapy directed against b cell maturation antigen (bcma), in patients with relapsed or refractory multiple myeloma. contract research & services > clinical trials > news view all clinical trials news or find news targeted to your interests 0' report store -- in the spotlight reliable, long-range wireless sensors for environmental monitoring grünenthal begins phase iii trials in complex regional pain syndrome astrazeneca, eli lilly terminate clinical trials of alzheimer's disease treatment lanabecestat advaxis doses first patient with adxs-neo cancer immunotherapy fda accepts cellenkos’ ind to begin clinical trial of ck0801 for bone marrow failure syndromes inside clinical trials clinical trials white papers publications by theme ctl laboratories contract research & services > clinical trials > white papers clinical trials suppliers spotlight suppliers by sector a-z production & manufacturing fine & speciality chemicals manufacturing process & production otc drug research drug delivery drug discovery & development contract research & services clinical trials contract research contract services automation it & software laboratory instrumentation inward investment packaging regulatory affairs # a b c d e f g h i j k l m n o p q r s t u v w x y z -- -- -- pbr website usage about us accessibility advertise with us contact us help privacy rss feeds site map dining club browse by sector browse by network business review sites produ

URL analysis for clinicaltrials.pharmaceutical-business-review.com

http://clinicaltrials.pharmaceutical-business-review.com/
http://clinicaltrials.pharmaceutical-business-review.com/news

Whois Information

Whois is a protocol that is access to registering information. You can reach when the website was registered, when it will be expire, what is contact details of the site with the following informations. In a nutshell, it includes these informations;

Domain Name: PHARMACEUTICAL-BUSINESS-REVIEW.COM
Registry Domain ID: 96790032_DOMAIN_COM-VRSN
Registrar WHOIS Server: whois.lcn.com
Registrar URL: https://www.lcn.com
Updated Date: 2017-07-06T09:42:04+01:00
Creation Date: 2003-04-14T05:09:49+01:00
Registrar Registration Expiration Date: 2019-04-14T09:09:49+01:00
Registrar: LCN.com Ltd
Registrar IANA ID: 602
Registrar Abuse Contact Email: [email protected]
Registrar Abuse Contact Phone: +44.1438342490
Domain Status: clientDeleteProhibited
Domain Status: clientTransferProhibited
Domain Status: clientUpdateProhibited
Registry Registrant ID:
Registrant Name: PDMG Plc IT Department
Registrant Organisation: Progressive Digital Media Group Plc
Registrant Street: Progressive House
Registrant Street: 2 Maidstone Road
Registrant City: Foots Cray, Sidcup
Registrant State: Kent
Registrant Postal Code: DA14 5HZ
Registrant Country: GB
Registrant Phone: +44.2082697700
Registrant Email: [email protected]
Registry Admin ID: AI-727110
Admin Name: PDMG Plc IT Department
Admin Organisation: Progressive Digital Media Group Plc
Admin Street: Progressive House
Admin Street: 2 Maidstone Road
Admin City: Foots Cray, Sidcup
Admin State: Kent
Admin Postal Code: DA14 5HZ
Admin Country: GB
Admin Phone: +44.2082697700
Admin Email: [email protected]
Registry Tech ID: AI-300624
Tech Name: LCN Hostmaster
Tech Organization: LCN.com Ltd
Tech Street: Units H, J, K, Gateway 1000, Whittle Way
Tech City: Stevenage
Tech State/Province: Herts
Tech Postal Code: SG1 2FP
Tech Country: GB
Tech Phone: +44.1438342490
Tech Fax: +44.1438300137
Tech Email: [email protected]
Name Server: ns.tmnplc.com
Name Server: ns2.tmnplc.com
Name Server: ns3.tmngroup.com
Name Server: ns4.tmngroup.com
DNSSec: Unsigned
URL of the ICANN WHOIS Data Problem Reporting System: http://wdprs.internic.net/
>>> Last update of WHOIS database: 2017-07-06T09:42:04+01:00 <<<

Domain Registration Service Provided By: LCN.com

The data in LCN.com's WHOIS database is provided by LCN.com for information
purposes, and to assist persons in obtaining information about or related to a
domain name registration record. LCN.com does not guarantee its accuracy.

By submitting a WHOIS query, you agree that you will use the data obtained only
for lawful purposes and that, under no circumstances will you use this data to:

(a) allow, enable, or otherwise support the transmission by e-mail, telephone,
or facsimile of mass, unsolicited, commercial advertising or solicitations to
entities other than the data recipient's own existing customers; or (b) enable
high volume, automated, electronic processes that send queries or data to the
systems of LCN.com, except as reasonably necessary to register domain names or
modify existing registrations.

By submitting this query, you agree to abide by this policy.

LCN.com reserves the right to modify these terms at any time.


*******************************************************************************
*******************************************************************************
** **
** Domain Registration Service Provided By: LCN.com **
** ------------------------------------------------ **
** **
** **
** - For award winning domain name services visit: **
** **
** https://www.lcn.com/domain_names **
** **
** - For powerful & reliable web hosting backed by a 30 day money **
** backed guarantee visit: **
** **
** https://www.lcn.com/web_hosting **
** **
** - For support visit: **
** **
** https://www.lcn.com/contact_us **
** **
*******************************************************************************
*******************************************************************************

  REGISTRAR LCN.COM LTD.

  REFERRER http://www.LCN.com

SERVERS

  SERVER com.whois-servers.net

  ARGS domain =pharmaceutical-business-review.com

  PORT 43

  SERVER whois.lcn.com

  ARGS pharmaceutical-business-review.com

  PORT 43

  TYPE domain

DOMAIN

  NAME pharmaceutical-business-review.com

NSERVER

  NS.TMNPLC.COM 91.208.117.43

  NS2.TMNPLC.COM 91.208.117.43

  NS3.TMNGROUP.COM (DOES NOT EXIST)

  NS4.TMNGROUP.COM (DOES NOT EXIST)

STATUS
clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited
clientTransferProhibited https://icann.org/epp#clientTransferProhibited
clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited

  CHANGED 2017-03-09

  CREATED 2003-04-14

  EXPIRES 2019-04-14

  REGISTERED yes

Mistakes

The following list shows you to spelling mistakes possible of the internet users for the website searched .